OncoMatch/Clinical Trials/NCT06376669

Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma

Is NCT06376669 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for renal cell carcinoma.

Phase 2RecruitingSidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06376669Data as of May 2026

This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.

Check if I qualify

Extracted eligibility criteria

Cancer type

Renal Cell Carcinoma

Prior therapy

Cannot have received: radiation therapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Sibley Memorial Hospital · Washington D.C., District of Columbia

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify